Kathy Reape, MD is the Chief Medical Officer at Spark Therapeutics and is responsible for all clinical, pharmacovigilance, and medical affairs activities in the company. She has more than 18 years of pharmaceutical industry experience in clinical drug development, and has overseen numerous clinical trials and been involved in the approvals of more than two dozen products including small molecules, biologics, biosimilars, and devices spanning a wide range of therapeutic areas. She has authored a number of abstracts and manuscripts and is named on several patents.
With Spark since 2015, she’s been responsible for global clinical programs utilizing gene therapy in rare diseases including hemophilia, metabolic and central nervous system disorders, and inherited retinal dystrophies. She was involved in Spark’s submission of the BLA and MAA for LUXTURNA® (voretigene neparvovec-ryzl), leading to US FDA approval in 2017 and EMA marketing authorization in 2018 indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Prior to joining Spark, Kathy was Senior Vice President, Head of Clinical Development, Global Brands R&D for Allergan, plc where she led the Clinical Development function for the entire brand R&D portfolio, including programs in ophthalmology, cardiovascular, gastrointestinal, anti-infectives, respiratory, women’s health, urology, dermatology/aesthetics, and central nervous system (CNS). Kathy has also held leadership positions in Clinical R&D and Medical Affairs at Teva Pharmaceuticals, Duramed Research, Barr Labs, and Wyeth Pharmaceuticals.
She received her MD from the University of Pennsylvania and completed her internship and residency at the University of Florida and the University of Medicine and Dentistry of New Jersey.